Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 9, 2006, Pages 1042-1047

  Namachivayam, Poongundran ^b   Theilen, Ulf ^b   Butt, Warwick W ^b   Cooper, Sian M ^b   Penny, Daniel J ^b   Shekerdemian, Lara S ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b NONE

Author keywords

Children; Nitric oxide; Pulmonary hypertension; Rebound; Sildenafil

Indexed keywords

NITRIC OXIDE; PLACEBO; SILDENAFIL;

ARTERIAL GAS; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; INFANT; LUNG ARTERY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REBOUND;

ADMINISTRATION, INHALATION; BLOOD PRESSURE; DOUBLE-BLIND METHOD; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PULMONARY ARTERY; RESPIRATION, ARTIFICIAL; TIME FACTORS;

EID: 33750602910     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200605-694OC     Document Type: Article

References (28)

1. Brown KL, Ridout DA, Goldman AP, Hoskote A, Penny DJ. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med 2003;31(1):28-33.
2. Beiderlinden M, Kuehl H, Boes T, Peters J. Prevalence of pulmonary hypertension associated with severe acute respiratory distress syndrome: predictive value of computed tomography. Intensive Care Med 2006;32:852-857.
3. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-1174.
4. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997;336:597-604.
5. Finer NN, Barrington KJ. Nitric oxide in respiratory failure in the newborn infant. Semin Perinatol 1997;21:426-440.
6. Miller OI, Celermajer DS, Deanfield JE, Macrae DJ. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994;108:487-494.
7. Curran RD, Mavroudis C, Backer CL, Sautel M, Zales VR, Wessel DL. Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension. Ann Thorac Surg 1995;60:1765-1771.
8. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev 2003;1:CD002787.
9. Miller OI, Tang SF, Keech A, Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995;346:51-52.
10. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996;62:1759-1764.
11. Schulze-Neick I, Werner H, Penny DJ, Alexi-Meskishvili V, Lange PE. Acute ventilatory restriction in children after weaning off inhaled nitric oxide: relation to rebound pulmonary hypertension. Intensive Care Med 1999;25:76-80.
12. Black SM, Heidersbach RS, McMullan DM, Bekker JM, Johengen MJ, Fineman JR. Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension. Am J Physiol 1999;277:H1849-H1856.
13. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 1999;104:231-236.
14. Thelitz S, Bekker JM, Ovadia B, Stuart RB, Johengen MJ, Black SM, Fineman JR. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs. J Thorac Cardiovasc Surg 2004;127:1285-1292.
15. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery. Intensive Care Med 2003;29:1996-2003.
16. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002;165:1098-1102.
17. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002;360:895-900.
18. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91:307-310.
19. Nakajima W, Ishida A, Arai H, Takada G. Methaemoglobinaemia after inhalation of nitric oxide in infant with pulmonary hypertension. Lancet 1997;350:1002-1003.
20. George TN, Johnson KJ, Bates JN, Segar JL. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr 1998;132:731-734.
21. Pierce CM, Peters MJ, Cohen G, Goldman AP, Petros AJ. Cost of nitric oxide is exorbitant. BMJ 2002;325:336.
22. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002;165:1098-1102.
23. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002;360:895-900.
24. Ryhammer PK, Shekerdemian LS, Penny DJ, Ravn HB. The effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. Pediatr Res 2006;59:762-766.
25. Kleinsasser A, Loeckinger A, Hoermann C, Puehringer F, Mutz N, Bartsch G, Lindner KH. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 2001;163:339-343.
26. Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998;115:875-882.
27. al-Alaiyan S, al-Omran A, Dyer D. The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Intensive Care Med 1996;22:1093-1095.
28. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002;53(Suppl 1):5S-12S.